New York, NY (PRWEB via PRWebDirect) May 21, 2007 -- TriMark Publications (http://www.trimarkpublications.com), a global leader in the biotechnology, healthcare and life sciences publishing, announces the release of its Cancer Diagnostic Testing report. Cancer testing is one of the most important growth opportunities for the next three to five years in the diagnostics segment. The National Cancer Institute estimates that about ten million Americans have or have had some form of cancer. Overall costs of the disease are $126 billion annually. Pharmaceutical companies are developing more than 300 new medicines for cancer, some of which are in development for more than one type of the disease, for a total of more than 500 ongoing R&D projects.
The goal of this TriMark Publications report is to review the market for tumor marker testing equipment and supplies using screening reagents and instruments for analysis of individual components in blood, serum or plasma. It defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments. Also examined are the subsections of each market segment, including: the physician office labs, hospital labs and commercial laboratories. Additionally, the numbers of institutions using this type of testing and the factors that influence purchases are discussed.
The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the clinical point-of-care market in the U.S. Each company is discussed in depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company’s market position. The following areas are addressed in this analysis:
•
DNA Markers
•
Serum Proteins
•
Enzymes
•
Occult Blood
•
Histology and In Situ Hybridization (ISH)
•
Cervical Cytology
•
Immunohistochemistry
•
In Vivo Detection Cancer Products
•
Radionuclides and X-Ray Detection Products
•
Human Papillomavirus (HPV) Testing
•
Bladder Cancer Testing
•
Tumor Assays for Adjuvant Chemotherapy
•
Organ Specific Tumor Markers
•
Colon Cancer
•
Prostate Cancer
•
Pancreatic Cancer
•
Breast Cancer
•
Ovarian Cancer
•
Cervical Cancer
•
Lung Cancer
•
Testicular Cancer
•
Bladder Cancer
•
Hepatic Cancer
•
Stomach Cancer
•
Malignant Melanoma
•
Acute Myeloid Leukemia (AML)
•
Acute Lymphoblastoid Leukemia (ALL)
•
Lymphoma
Reasons to Buy TriMark Content
•
Content is updated regularly in accordance with changes in the industries our reports cover.
•
Content is specifically designed to help individuals who work in the industries the content covers remain competitive in the marketplace.
•
Content contains detailed sales data, market share information and emerging trends, all of which impact the sectors biotechnology, healthcare, pharmaceutical and medical devices companies operate in.
•
Your competitors are buying TriMark content!
About TriMark Publications, LLC
Based in New York City, TriMark Publications is a global leader in the biotechnology, healthcare and life sciences publishing. TriMark’s market research covers the following topics:
•
Anti-Aging Products and Services
•
China's In Vitro Diagnostic Testing Industry
•
Contract Drug Discovery Industry
•
European Hospital Purchasing Practices
•
Flow Cytometry
•
Food Industry Additives
•
High-Performance Films
•
Hospital Supply Chain Management
•
In Vitro Diagnostic Industry Leading Players Comparison and Review
•
Independent Clinical Laboratories
•
India's In Vitro Diagnostic Testing Industry
•
Monoclonal Antibody Therapy
•
PET and SPECT-CT Imaging Technologies
•
Prescription Ophthalmic Drug Market
•
Protein and Antibody Microarrays Markets
•
Robotics and Orthopedic Surgery
•
Targeted Cancer Therapies Markets
•
Therapeutic Drug Market for Acne
•
Therapeutic Radiopharmaceuticals Markets
•
U.S. Market for Gastrointestinal Pharmaceuticals
•
Urinary Incontinence Markets
•
World Pharmaceutical Drug Market
•
Worldwide Psychotherapeutic Drug Market
For more information, please visit http://www.trimarkpublications.com.
Important Notice
The statements contained in this news release that are forward-looking are based on current expectations that are subject to a number of uncertainties and risks, and actual results may differ materially.
Contact
TriMark Publications, LLC
212.265.9877
www.trimarkpublications.com
# # #
|
